6 completed, 2 active not recruiting, 1 not yet recruiting, 1 recruiting. 5 Phase 3, 3 Phase 4, 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 4 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Insud Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage Oxytocin sublingual, Oxytocin IM - Post Partum Hemorrhage | Phase 2 | Not yet recruiting | Insud Pharma | 330 | 2026-05-30 | 2026-04-23 |
| Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness Pre-screening Phase, Screenig Phase, Randomization - Soil-Transmitted Helminths | Phase 3 | Recruiting | Insud Pharma | 20000 | 2025-09-01 | 2025-09-15 |
| Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females Drospirenone - Contraception, Change in Bone Mineral Density | Phase 3 | Completed | Insud Pharma | 1542 | 2022-08-02 | 2025-10-08 |
| LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet - Change in Bone Mineral Density, Bone Loss | Phase 4 | Active not recruiting | Insud Pharma | 1536 | 2022-03-28 | 2026-04-09 |
| A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System - Residual Drug Amount of EE and LNG | Phase 4 | Completed | Insud Pharma | 28 | 2021-10-25 | 2026-08-27 |
| Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50 Ivermectin, Placebo - COVID-19, SARS-CoV-2 | Phase 3 | Terminated | Insud Pharma | 249 | 2021-01-18 | 2023-08-15 |
| A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles LPRI424 (dienogest/ethinylestradiol) - Contraception | Phase 3 | Completed | Insud Pharma | 1034 | 2019-12-03 | 2023-11-14 |
| Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease Benznidazole - Chagas Disease | Phase 3 | Active not recruiting | Insud Pharma | 178 | 2019-09-19 | 2026-04-21 |
| Benznidazole Absorption, Metabolism and Excretion Study [14C]-Benznidazole - Healthy Male Subjects | Phase 1 | Completed | Exeltis France | 6 | 2018-07-16 | 2018-11-14 |
| Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) T1, T2, T3, T1,T3,T2, T2,T1,T3 - Helminthiasis | Phase 1 | Completed | Insud Pharma | 54 | 2016-03-01 | 2017-06-02 |
| Safety and Tolerability of Metronidazole Gel 1.3% Metronidazole Gel - Vaginosis, Bacterial | Phase 4 | Completed | Insud Pharma | 60 | 2015-08-12 | 2023-08-15 |
Bone Diseases, Metabolic (1) · COVID-19 (1) · Chagas Disease (1) · Contraception Behavior (1) · Helminthiasis (1) · Hookworm Infections (1) · Osteoporosis (1) · Postpartum Hemorrhage (1) · Vaginosis, Bacterial (1)
Ethinyl Estradiol (2) · drospirenone (2) · Ethinyl Estradiol-Norgestrel Combination (1) · Ivermectin (1) · Levonorgestrel (1) · Mass Drug Administration (1) · Random Allocation (1) · Tablets (1) · Transdermal Patch (1) · Triiodothyronine (1) · Watchful Waiting (1) · benzonidazole (1) · dienogest (1)
United States (5) · Argentina (1) · Bolivia (1) · Canada (1) · Colombia (1) · Czechia (1) · Ghana (1) · Kenya (1) · Nigeria (1) · Poland (1) · Spain (1) · United Kingdom (1)
Enrico Colli, MD (4) · Alejandro Krolewiecki, MD (1) · Gina Giannantoni-Ibelli, MS (1) · Sunu Valasseri, MBBS, MSc (1)
2015 (1)